Oral anticoagulation strategies after a first idiopathic venous thromboembolic event

American Journal of Medicine

Volumn 118, Issue 6, 2005, Pages 625-635

  Aujesky, Drahomir ^a,b   Smith, Kenneth J ^a   Roberts, Mark S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Effectiveness; Idiopathic venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEMOGRAPHY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PULMONARY EMBOLISM; QUALITY OF LIFE; RECURRENCE; VENOUS THROMBOSIS; WARFARIN;

EID: 19544375219     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.02.018     Document Type: Article

References (55)

1. P. Prandoni, A.W. Lensing, A. Cogo The long-term clinical course of acute deep venous thrombosis Ann Intern Med. 125 1996 1 7
2. H.R. Buller, G. Agnelli, R.D. Hull Antithrombotic therapy for venous thromboembolic disease the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 401S 428S
3. M.N. Levine, G. Raskob, R.J. Beyth Hemorrhagic complications of anticoagulant treatment the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 287S 310S
4. L. Pinede, J. Ninet, P. Duhaut Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis Circulation 103 2001 2453 2460
5. G. Agnelli, P. Prandoni, M.G. Santamaria Warfarin Optimal Duration Italian Trial Investigators Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis N Engl J Med. 345 2001 165 169
6. G. Agnelli, P. Prandoni, C. Becattini Extended oral anticoagulant therapy after a first episode of pulmonary embolism Ann Intern Med. 139 2003 19 25
7. P.M. Ridker, S.Z. Goldhaber, E. Danielson Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism N Engl J Med. 348 2003 1425 1434
8. C. Kearon, J.S. Ginsberg, M.J. Kovacs Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism N Engl J Med. 349 2003 631 639
9. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism Thorax 58 2003 470 483
10. C. Kearon Long-term management of patients after venous thromboembolism Circulation 110 2004 110 118
11. F.J. Van der Meer, F.R. Rosendaal, J.P. Vandenbroucke, E. Briet Bleeding complications in oral anticoagulant therapy. An analysis of risk factors Arch Intern Med. 153 1993 1557 1562
12. F.J. Van der Meer, F.R. Rosendaal, J.P. Vandenbroucke, E. Briet Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants Thromb Haemost 76 1996 12 16
13. P.A. Kyrle, E. Minar, C. Bialonczyk The risk of recurrent venous thromboembolism in men and women N Engl J Med. 350 2004 2558 2563
14. S. Schulman, K. Wahlander, T. Lundstrom, S.B. Clason, H. Eriksson, T.I. Investigators Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran N Engl J Med. 349 2003 1713 1721
15. F.A. Sonnenberg, J.R. Beck Markov models in medical decision making a practical guide Med Decis Making 13 1993 322 338
16. M.C. Weinstein, J.E. Siegel, M.R. Gold Recommendations of the Panel on Cost-effectiveness in Health and Medicine JAMA 276 1996 1253 1258
17. C. Kearon, M. Gent, J. Hirsh A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N Engl J Med. 340 1999 901 907
18. C. Kearon Rate of recurrent venous thromboembolism (VTE) after completing two years of anticoagulation for a first episode of idiopathic VTE [Abstract] Thromb Haemost. 7 Suppl. 2001 P794
19. R.H. White, T. McKittrick, J. Takakuwa National Consortium of Anticoagulation Clinics Management and prognosis of life-threatening bleeding during warfarin therapy Arch Intern Med. 156 1996 1197 1201
20. T.C. Collins, N.J. Petersen, T.J. Menke Short-term, intermediate-term, and long-term mortality in patients hospitalized for stroke J Clin Epidemiol. 56 2003 81 87
21. J. Rosand, M.H. Eckman, K.A. Knudsen The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage Arch Intern Med. 164 2004 880 884
22. H. Decousus, A. Leizorovicz, F. Parent Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis N Engl J Med. 338 1998 409 415
23. E. Arias United States life tables, 2000. National vital statistics reports; vol 51, no 3 2002 National Center for Health Statistics Hyattsville, MD
24. P. Lindmarker, S. Schulman, M. Sten-Linder The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation Thromb Haemost. 81 1999 684 689
25. M. Cushman, A.W. Tsai, R.H. White Deep vein thrombosis and pulmonary embolism in two cohorts the longitudinal investigation of thromboembolism etiology Am J Med. 117 2004 19 25
26. V. Pengo, C. Legnani, F. Noventa, G. Palareti Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding a multicenter inception cohort study Thromb Haemost. 85 2001 418 422
27. J.R. Beck, S.G. Pauker, J.E. Gottlieb A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making Am J Med. 73 6 1982 889 897
28. M.K. Gould, A.D. Dembitzer, G.D. Sanders, A.M. Garber Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. a cost-effectiveness analysis Ann Intern Med. 130 1999 789 799
29. A.D. Auerbach, G.D. Sanders, J. Hambleton Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis Am J Med. 116 2004 816 828
30. From the Medicare Provider Analysis and Review (MEDPAR) of Short-Stay Hospitals Web site. Available at: http://cms.hhs.gov/statistics/medpar/default. asp. Accessed September 30, 2004.
31. M.R. Gold, P. Franks, K.I. McCoy, D.G. Fryback Toward consistency in cost-utility analyses using national measures to create condition-specific values Med Care 36 1998 778 792
32. Drug Topics Red Book 2002 Medical Economics Montvale, NY
33. From the Centers for Medicare & Medicaid Services web site. Available at: http://cms.hhs.gov/providers/pufdownload/default.asp. Accessed September 30, 2004.
34. From the U.S. Bureau of Labor Statistics Web site. Available at: http://www.bls.gov/data/. Accessed September 30, 2004.
35. R.A. Hirth, M.E. Chernew, E. Miller Willingness to pay for a quality-adjusted life year in search of a standard Med Decis Making 20 3 2000 332 342
36. P. Doubilet, C.B. Begg, M.C. Weinstein Probabilistic sensitivity analysis using Monte Carlo simulation a practical approach Med Decis Making 5 1985 157 177
37. A.A. Stinnett, J. Mullahy Net health benefits a new framework for the analysis of uncertainty in cost-effectiveness analysis Med Decis Making 18 1998 S68 S80
38. C.J. Van Dongen, R. Vink, B.A. Hutten The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event a meta-analysis Arch Intern Med. 163 2003 1285 1293
39. L.A. Frazee, D.L. Chomo Duration of anticoagulant therapy after initial idiopathic venous thromboembolism Ann Pharmacother. 37 2003 1489 1496
40. J.D. Douketis, C. Kearon, S. Bates Risk of fatal pulmonary embolism in patients with treated venous thromboembolism JAMA 279 1998 458 462
41. R.J. Beyth, L.M. Quinn, C.S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med. 105 1998 91 99
42. P.S. Wells, M.A. Forgie, M. Simms The outpatient bleeding risk index validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism Arch Intern Med. 163 2003 917 920
43. F.P. Sarasin, H. Bounameaux Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis BMJ 316 7125 1998 95 99
44. M.H. Eckman, S.K. Singh, J.K. Erban, G. Kao Testing for factor V Leiden in patients with pulmonary or venous thromboembolism a cost-effectiveness analysis Med Decis Making 22 2002 108 124
45. M. Marchetti, A. Pistorio, G. Barosi Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis Thromb Haemost. 84 5 2000 752 757
46. A.G. Van den Belt, B.A. Hutten, M.H. Prins, P.M. Bossuy Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S--a decision analysis Thromb Haemost. 84 2000 758 763
47. V. Pengo, A.W. Lensing, M.H. Prins Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism N Engl J Med. 350 2004 2257 2264
48. L.A. Linkins, P.T. Choi, J.D. Douketis Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism a meta-analysis Ann Intern Med. 139 2003 893 900
49. C. Luk, P.S. Wells, D. Anderson, M.J. Kovacs Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy Am J Med. 111 2001 270 273
50. D.M. Becker, J.T. Philbrick, J.B. Selby Inferior vena cava filters. Indications, safety, effectiveness Arch Intern Med. 152 1992 1985 1994
51. L.A. Lenert, R.M. Soetikno Automated computer interviews to elicit utilities potential applications in the treatment of deep venous thrombosis J Am Med Inform Assoc. 4 1997 49 56
52. B.F. Gage, A.B. Cardinalli, G.W. Albers, D.K. Owens Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation JAMA 274 1995 1839 1845
53. M. Marchetti, A. Pistorio, M. Barone Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism a cost-effectiveness analysis Am J Med. 111 2001 130 139
54. J. Teng, N.E. Mayo, E. Latimer Costs and caregiver consequences of early supported discharge for stroke patients Stroke 34 2003 528 536
55. J.A. Caprini, M.F. Botteman, J.M. Stephens Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States Value Health 6 2003 59 74